The risk of COVID-19 in patients with psoriasis: A retrospective cohort study

J Am Acad Dermatol. 2022 Dec;87(6):1395-1398. doi: 10.1016/j.jaad.2022.07.040. Epub 2022 Sep 20.

Authors

Jashin J Wu¹, Jeffrey Liu², Akshitha Thatiparthi³, Amylee Martin⁴, Alexander Egeberg⁵

Affiliations

¹ University of Miami Miller School of Medicine, Miami, Florida. Electronic address: jashinwu@gmail.com.
² Keck School of Medicine, University of Southern California, Los Angeles, California.
³ Western University of Health Sciences, Pomona, California.
⁴ School of Medicine, University of California Riverside, Riverside, California.
⁵ Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

No abstract available

Keywords: COVID-19; apremilast; biologics; dermatology; methotrexate; psoriasis.

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
COVID-19*
Humans
Psoriasis* / chemically induced
Psoriasis* / complications
Psoriasis* / epidemiology
Retrospective Studies
Thalidomide / therapeutic use

Substances

Thalidomide
Anti-Inflammatory Agents, Non-Steroidal